---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000095"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:58:58.270678+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arvinas/Pfizer vepdegestrant VERITAC-2: PFS benefit in ESR1m patients; NDA in H2 2025

## Summary
- In ESR1m patients, vepdegestrant reduced progression/death risk by 43% (HR=0.57); median PFS 5.0 vs 2.1 months (p<0.001).
- ITT population median PFS 3.7 vs 3.6 months (HR=0.83, p=0.07), not statistically significant.
- Secondary endpoints in ESR1m: ORR 18.6% vs 4.0% (OR 5.45), CBR 42.1% vs 20.2% (OR 2.88).
- Safety profile generally well tolerated; GI events low (nausea 13.5%); discontinuation 2.9% vs 0.7%.
- Companies plan to submit NDA to FDA in H2 2025; OS data immature at analysis.

## SEC filing metadata
- accession: 0001655759-25-000095
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000095/0001655759-25-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000095/arvn-20250531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000095
- JSON: https://secwatch.observer/filing/0001655759-25-000095.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.